Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.

There were significant increases in frequency in these cells between day 1 and day 22 in the MAP-FA-15 (0.005% to 0.048%, p < 0.001) and MAP-UA-15 (0.002% to 0.047%, p < 0.001) groups, and an increase that did not reach statistical significance in the IM-QIV-15 groups (0.004% to 0.026%, p = 0.05), but again, there were no differences in the MBC frequency in the vaccine groups at day 22 (MAP-FA-15 compared with IM-QIV-15, p > 0.99; MAP-UA-15 compared with IM-QIV-15, p > 0.99; MAP-FA-15 compared with MAP-UA-15, p > 0.99; Fig 8C and Fig 8D ).

also in 111,027 other papers

The expansion in the MAP-UA-15 groups did not achieve significance, probably because of intragroup variability (0.128% to 0.569%, p = 0.17).

also in 1,397 other papers